ONCORESPONSE
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, to interrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive ... immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
ONCORESPONSE
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.oncoresponseinc.com
Total Employee:
11+
Status:
Active
Contact:
206-805-1600
Email Addresses:
[email protected] [email protected] [email protected] [email protected] [email protected] [email protected] [email protected]
Total Funding:
103.1 M USD
Technology used in webpage:
SPF Domain Not Resolving Euro Microsoft Exchange Online Office 365 Mail GoDaddy DNS GoDaddy Zoom Video Conferencing Zoom KnowBe4
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-11-07 | Paganini Biopharma | Paganini Biopharma acquired by OncoResponse | N/A |
Investors List
Bering Capital
Bering Capital investment in Series C - OncoResponse
ARCH Venture Partners
ARCH Venture Partners investment in Series C - OncoResponse
RiverVest
RiverVest investment in Series C - OncoResponse
Qatar Investment Authority
Qatar Investment Authority investment in Series C - OncoResponse
Canaan Partners
Canaan Partners investment in Series C - OncoResponse
Redmile Group
Redmile Group investment in Series C - OncoResponse
Yonjin Venture
Yonjin Venture investment in Series C - OncoResponse
3B Future Health Fund
3B Future Health Fund investment in Series C - OncoResponse
Magnetar Capital
Magnetar Capital investment in Series C - OncoResponse
Qatar Investment Authority
Qatar Investment Authority investment in Series B - OncoResponse
Official Site Inspections
http://www.oncoresponseinc.com
- Host name: 132.44.180.107.host.secureserver.net
- IP address: 107.180.44.132
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "OncoResponse"
OncoResponse - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +1 206 805 1600 OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully …See details»
About OncoResponse - About - OncoResponse
609 Main St, Suite 4200 Houston, TX 77002 United States 1124 Columbia St, Suite 300 Seattle, WA 98104 United States. [email protected] P: 206-805-1600 F: 206-805-1699See details»
OncoResponse Company Profile | Management and Employees …
OncoResponse Profile and History. OncoResponse, Inc., an immuno-oncology focused biotech company, in a broad strategic alliance with MD Anderson Cancer Center, uses a proprietary B …See details»
Leadership Team - About - OncoResponse
Chris Russell, MBA Chief Financial Officer. Chris Russell provides financial and operational leadership at OncoResponse. He has over 30 years of experience as a growth company executive and entrepreneur, launching highly successful …See details»
OncoResponse Company Profile 2024: Valuation, …
OncoResponse General Information Description. Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of cancer patients who have responded exceptionally well to …See details»
OncoResponse - LinkedIn
OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders.See details»
ONCORESPONSE, INC. Company Profile | Seattle, WA - Dun
Find company research, competitor information, contact details & financial data for ONCORESPONSE, INC. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
OncoResponse - The Org
OncoResponse leverages the power of the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody …See details»
OncoResponse Company Profile - Craft
OncoResponse is an immuno-oncology company. The Company is engaged in providing cancer research into immunotherapies. It licensed the I-STAR™ platform, developed to interrogate …See details»
Oncoresponse, Inc. - Company Profile - Corporation Wiki
Oncoresponse, Inc. Overview. Oncoresponse, Inc. filed as a Statement & Designation By Foreign Corporation in the State of California on Thursday, June 10, 2021 and is approximately two …See details»
OncoResponse Company Overview, Contact Details
[email protected]: 98%. [email protected]: [email protected]: 2%. [email protected]: [email protected]: …See details»
OncoResponse - VentureRadar
OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. The OncoResponse... ... Find out more ...See details»
OncoResponse Company Profile Funding & Investors | YourStory
OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders.See details»
Investors - About - OncoResponse
Helsinn Investment Fund The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core …See details»
OncoResponse (USA) Funding: $130.1M - Medical Startups
Dec 10, 2024 OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for...See details»
OncoResponse - Company Profile - Tracxn
Oct 22, 2024 OncoResponse ranks 10th among 481 active competitors. 173 of its competitors are funded while 105 have exited. Overall, OncoResponse and its competitors have raised …See details»
Pipeline - OncoResponse
609 Main St, Suite 4200 Houston, TX 77002 United States 1124 Columbia St, Suite 300 Seattle, WA 98104 United States. [email protected] P: 206-805-1600 F: 206-805-1699See details»
Technology Platform - Science - OncoResponse
609 Main St, Suite 4200 Houston, TX 77002 United States 1124 Columbia St, Suite 300 Seattle, WA 98104 United States. [email protected] P: 206-805-1600 F: 206-805-1699See details»